PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse

JTI by 2FIRSTS, edited by Sophia
Apr.09.2024
PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
PMI launches VEEV vape brand in Germany, competing with Vuse from China and BAT, targeting tobacco users.

According to the German media Nouvelles, Philip Morris International (PMI) has decided to launch its vape brand VEEV in Germany, thereby competing with major Chinese manufacturers as well as the rival product Vuse from British American Tobacco (BAT). Although PMI had already included e-cigarettes in its product line several years ago and sold them in other countries such as Poland, the Czech Republic, and Greece, it had never sold e-cigarettes in Germany.

 

PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
Disposable product VEEV NOW | Image source: PMI

 

PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
Pod-system product VEEV ONE | Image source: PMi

 

PMI's Chief Spokesperson, Torsten Albig, stated in a media interview, "We have made extensive and intensive efforts at the government level to ban the sale of disposable e-cigarettes, but to no avail. Therefore, we have decided to enter this market as well."

 

Among teenagers and young people, disposable e-cigarettes are particularly popular. However, the German Federal Ministry of Food and Agriculture appears to be considering banning the use of mint as an ingredient in e-cigarettes in order to reduce the possibility of e-cigarettes gaining market share. However, policymakers in other European countries have responded more uniformly to this issue. For example, countries like France and Belgium will ban the sale of disposable e-cigarettes starting next year.

 

PMI is planning to launch a rechargeable e-cigarette while also selling disposable products. "But this should only be a test product," Albig explained.

 

PMI's current sales policy is to offer a free VEEV charging device with the purchase of three disposable e-cigarettes. This promotion is taking place at participating retailers and the company's IQOS stores. Altria announced that VEEV will be introduced in stores located in major cities that previously only sold heated tobacco products.

 

However, he also admitted that the introduction of e-cigarettes is not just a response to policy loopholes.

 

He pointed out:

 

If we want to achieve our global goals as a group and have over two-thirds of our net revenue contributed by tobacco alternatives by 2030, we cannot afford to leave the German market.

 

In this country, PMI and its IQOS heated tobacco products only occupy a market share of 6%, slightly higher in major cities at just over 10%. Meanwhile, their Marlboro cigarettes hold a 25% market share.

 

PMI hopes to attract smokers with the e-cigarette VEEV and provide competitive pricing: the disposable version will be sold for 7.90 euros, while two refill pods for the reusable system will be priced at 8.90 euros.

 

Although competitors' disposable e-cigarettes are generally priced at ten euros or higher, PMI has decided to challenge their position. Alberg remains calm about the ban on using mint or flavorings in e-cigarettes. He said, "If that's how it is, then so be it. Our products are not meant to attract young people, but to satisfy cigarette smokers who are already accustomed to the taste of tobacco.

 

The World Health Organization has clearly stated that alternative tobacco products are not healthier than traditional tobacco. At the same time, scientists who receive funding from the tobacco industry for research are often suspected of lobbying for the tobacco industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
A study by CDC Foundation researchers found no sustained decline in e-cigarette sales across Alabama, Oklahoma and Louisiana, the first three U.S. states to implement e-cigarette directory laws. Louisiana initially saw a significant sales decline, followed by a rebound and a persistent reduction in product availability. Sales also shifted from nontobacco-flavored disposables toward prefilled cartridges, with Vuse Alto driving much of the increase in menthol cartridges. By April 2025, unlisted products still accounted for more than half of e-cigarette nicotine sales in all three states.
Sep.18
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09